INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 PREDICTS INSULIN SENSITIVITY AND INSULIN AREA-UNDER-THE-CURVE IN OBESE, NONDIABETIC ADOLESCENTS.
OBJECTIVE
To compare fasting insulin-like growth factor binding protein 1 (IGFBP-1) to other fasting indices as a surrogate marker of insulin sensitivity and resistance calculated from a 3-hour oral glucose tolerance test (oGTT).


METHODS
Fasting IGFBP-1 and oGTT were performed at 0 (n = 77), 52 (n = 54), and 100 (n = 38) weeks in a study investigating metformin treatment of obesity in adolescents. Insulin area-under-the-curve (IAUC) and the composite insulin sensitivity index (CISI) calculated from the oGTT were compared to fasting IGFBP-1, homeostasis model assessment-insulin resistance, and corrected insulin release at the glucose peak (CIRgp).


RESULTS
IGFBP-1 and the ratio of IGFBP-1 to fasting insulin were significantly correlated with indices based on timed sampling, including IAUC, CISI, and CIRgp. In addition, a significant effect of IGFBP-1, but not IGFBP-1 to insulin at time zero, was observed for IAUC and CISI.


CONCLUSIONS
Our results indicate that fasting IGFBP-1 may be a useful marker of insulin sensitivity and secretion.
Phillip D K
PD
Lee
Robert H
RH
Lustig
Carine
C
Lenders
Jacques
J
Baillargeon
Darrell M
DM
Wilson
D000293:Adolescent; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000032:analysis / Q000097:blood*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D063766:Pediatric Obesity / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D011379:Prognosis
D015415:Biomarkers; D001786:Blood Glucose; D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1; D008687:Metformin